Grade Post Therapy Clin (yc)
Notes
**Note 1:** Leave post therapy grade blank when * No neoadjuvant therapy * Clinical or pathological case only * Neoadjuvant therapy completed, no microscopic exam is done prior to surgery/resection of primary tumor * There is only one grade available and it cannot be determined if it is clinical, pathological, post therapy clinical or post therapy pathological **Note 2:** Assign the highest grade from the microscopically sampled specimen of the primary site following neoadjuvant therapy or primary systemic/radiation therapy. * Per clarification from the CAP Cancer Committee based on the CAP Protocol, the following histologies must be assigned a G3 (code 3): Serous, clear cell, undifferentiated/de-differentiated carcinomas, carcinosarcomas, and mixed mesodermal tumors (Mullerian/MMMT) are *high risk (high grade)* **Note 3:** For endometrioid carcinomas only * If “low grade” is documented, code 2 (FIGO Grade 2) * If “high grade” is documented, code 3 (FIGO Grade 3)**Note 3:** If there are multiple tumors with different grades abstracted as one primary, code the highest grade. **Note 4:** If there are multiple tumors with different grades abstracted as one primary, code the highest grade. **Note 5:** G3 includes anaplastic. **Note 6:** Code 9 (unknown) when * Microscopic exam is done after neoadjuvant therapy and grade from the primary site is not documented * Microscopic exam is done after neoadjuvant therapy and there is no residual cancer * Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is available| Code | Description |
|---|---|
| 1 | G1 FIGO Grade 1 G1: Well differentiated |
| 2 | G2 FIGO Grade 2 G2: Moderately differentiated |
| 3 | G3 FIGO Grade 3 G3: Poorly differentiated or undifferentiated |
| 9 | Grade cannot be assessed (GX); Unknown |
| <BLANK> | See Note 1 |